pharma · Cystic Fibrosis · Multiple Sclerosis · RARE
Ultragenyx UK
Ultragenyx UK Limited
UGenDx is a pharma organization headquartered in NOVATO, CA, GB. It trades on NYSE under ticker RARE. Primary therapeutic focus areas include Cystic Fibrosis, Multiple Sclerosis, Fanconi's Anemia, Hereditary Inclusion Bo
Newcastle upon tyne, NE128RL, GB, NOVATO, CA HQ
2024 Founded
2 Employees
Public company Type
RARE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Newcastle upon tyne, NE128RL, GB, NOVATO, CA
- Founded
- 2024
- Employees
- 2
- Programs
- 201
- Drugs
- 168
- Patents
- 23
DTX101
Phase 2 · gene therapy · Hemophilia B
DTX101 for Hemophilia B is a Phase 2 program (gene_therapy) at Ultragenyx UK Limited with 1 ClinicalTrials.gov record(s).
Internal code 101HEMB01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ultragenyx UK Limited
- Phase
- Phase 2
- Modality
- gene_therapy
- Indication
- Hemophilia B
- Status
- terminated
- Trials
- 1